olivLaw · US equity research
Edgewell Personal Care Company EPC
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Edgewell Personal Care is a global maker and marketer of personal care products spanning wet shaving, sun and skin care. It is refocusing after selling its Feminine Care business, with fiscal 2025 net sales of about 2223.5 million USD, slightly lower year on year, making fiscal 2026 a period of repositioning.
At the close of 05 Nov 2026, Edgewell Personal Care Company (EPC) stock was 28.56 USD (−3.71% on the day), with market capitalisation 1.3 bn USD, dividend yield 2.10%, beta 0.52, 52-week range 15.91–29.66 USD. Latest reported quarter (Q3 2026): revenue of 570.1 m USD (+1.7% YoY), net income of 13.7 m USD (−52.9% YoY), diluted EPS 0.29 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.1
- neutral
- Bollinger (20, 2)
- 27.16 – 29.27
- in the upper half of the band · %B 0.67 · band width 7.5%
- SMA 50 / 200
- 27.80 / 24.11
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.27 / 0.20
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +6.3% | −1.1% | +7.4 pp | — |
| 3 months | +1.6% | −0.5% | +2.0 pp | — |
| 6 months | +31.9% | +4.4% | +27.5 pp | — |
| Year to date | +67.5% | +12.3% | +55.2 pp | — |
| 1 year | +48.9% | +13.5% | +35.4 pp | +1.7% |
| 3 years | −20.6% | +76.4% | −97.0 pp | −15.7% |
| 5 years | −25.6% | +63.7% | −89.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 517.6 m | 415.1 m | 516.6 m | 560.4 m | 731.4 m | 422.8 m | 519.5 m | 570.1 m |
| Cost of revenue | 304.8 m | 242.6 m | 279.7 m | 310.3 m | 465.9 m | 261.8 m | 302.6 m | 327.6 m |
| Gross profit | 212.8 m | 172.5 m | 236.9 m | 250.1 m | 265.5 m | 161.0 m | 216.9 m | 242.5 m |
| Research & development | 16.3 m | 13.4 m | 13.4 m | 13.5 m | 17.4 m | 13.8 m | 14.9 m | 13.3 m |
| SG&A | 109.2 m | 99.6 m | 102.8 m | 100.7 m | 121.9 m | 102.4 m | 111.0 m | 108.3 m |
| Operating income | 20.4 m | 9.3 m | 49.0 m | 45.0 m | -6.6 m | -18.9 m | 18.4 m | 25.0 m |
| Depreciation & amortisation | 21.4 m | 21.7 m | 21.8 m ≈ | 22.1 m ≈ | 23.2 m | 21.3 m | 19.1 m ≈ | 18.6 m ≈ |
| Interest expense | 17.5 m | 18.8 m | 20.2 m | 19.4 m | 14.8 m | 19.3 m | 17.9 m | 16.7 m |
| Pre-tax income | 5.4 m | -12.7 m | 31.4 m | 28.5 m | -23.5 m | -36.9 m | 7.9 m | 18.0 m |
| Income tax | -3.4 m | -2.6 m | 10.6 m | 7.0 m | -16.8 m | -7.7 m | 3.9 m | 5.7 m |
| Net income | 8.8 m | -2.1 m | 29.0 m | 29.1 m | -30.6 m | -65.7 m | -10.6 m | 13.7 m |
| Diluted EPS | 0.18 ≈ | -0.04 | 0.60 | 0.62 | -0.66 ≈ | -1.41 | -0.22 | 0.29 |
| Operating cash flow | -388.3 m | -115.6 m | 45.1 m ≈ | 114.8 m ≈ | 74.1 m | -125.9 m | 54.3 m ≈ | 118.7 m ≈ |
| Capex | 25.9 m | 16.8 m | 17.1 m ≈ | 15.5 m ≈ | 27.6 m | 11.6 m | 14.0 m ≈ | 15.6 m ≈ |
| Dividends paid | 7.4 m | 7.9 m | 7.3 m ≈ | 7.2 m ≈ | 6.9 m | 7.4 m | 7.1 m ≈ | 7.0 m ≈ |
| Share repurchases | 18.3 m | 30.3 m | 35.4 m ≈ | 24.5 m ≈ | 0 | 0 | 15.8 m ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2 bn | 2.1 bn | 1.9 bn | 2.1 bn | 2.2 bn | 2.3 bn | 2.3 bn | 2.2 bn |
| Revenue YoY | −2.8% | −4.2% | −8.9% | +7.1% | +4.0% | +3.7% | +0.1% | −1.3% |
| Net income | 103.3 m | -372.2 m | 67.6 m | 117.8 m | 99.5 m | 114.7 m | 98.6 m | 25.4 m |
| Net income YoY | +1,712.3% | −460.3% | unavailable | +74.3% | −15.5% | +15.3% | −14.0% | −74.2% |
| Diluted EPS | 1.90 | -6.88 | 1.24 | 2.13 | 1.85 | 2.21 | 1.97 | 0.53 |
| Diluted EPS YoY | +1,800.0% | −462.1% | unavailable | +71.8% | −13.1% | +19.5% | −10.9% | −73.1% |
| net % | 4.6% | -17.4% | 3.5% | 5.6% | 4.6% | 5.1% | 4.4% | 1.1% |
| Free cash flow | 197.4 m | 132.6 m | 184.9 m | 172.2 m | 45.6 m | -265.6 m | -287.5 m | 41.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Sept 2025
- Cash
- 225.7 m USD
- Financial debt
- 1.4 bn USD
- Net debt
- 1.2 bn USD
- Equity
- 1.6 bn USD
- Total assets
- 3.8 bn USD
- Debt / equity
- 0.89x
- Current ratio
- 1.76x
- ROE
- 1.6%
- ROA
- 0.7%
- FCF margin
- 1.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.9 bn | 2.1 bn | 2.2 bn | 2.3 bn | 2.3 bn | 2.2 bn | SEC (XBRL)· 18 Nov 2025verified |
| Cost of revenue | 1.1 bn | 1.1 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | SEC (XBRL)· 18 Nov 2025verified |
| Gross profit | 880.9 m | 951.2 m | 880.5 m | 940.8 m | 955.7 m | 924.9 m | SEC (XBRL)· 18 Nov 2025verified |
| Research & development | 55.3 m | 57.8 m | 55.5 m | 58.5 m | 58.4 m | 57.6 m | SEC (XBRL)· 18 Nov 2025verified |
| SG&A | — | — | — | 409.6 m | 430.1 m | 425.0 m | SEC (XBRL)· 18 Nov 2025verified |
| Operating income | 176.0 m | 239.9 m | 182.3 m | 227.0 m | 199.3 m | 96.6 m | SEC (XBRL)· 18 Nov 2025verified |
| Depreciation & amortisation | 88.8 m | 87.1 m | 89.9 m | 91.4 m | 88.0 m | 88.8 m | SEC (XBRL)· 18 Nov 2025verified |
| EBITDA | 264.8 m ≈ | 327.0 m ≈ | 272.2 m ≈ | 318.4 m ≈ | 287.3 m ≈ | 185.4 m ≈ | SEC (XBRL)· 18 Nov 2025derived |
| Interest expense | 61.2 m | 67.9 m | 71.4 m | 78.5 m | 76.5 m | 73.2 m | SEC (XBRL)· 18 Nov 2025verified |
| Pre-tax income | 87.3 m | 147.1 m | 124.1 m | 147.7 m | 120.9 m | 23.6 m | SEC (XBRL)· 18 Nov 2025verified |
| Income tax | 19.7 m | 29.3 m | 24.6 m | 33.0 m | 22.3 m | -1.8 m | SEC (XBRL)· 18 Nov 2025verified |
| Net income | 67.6 m | 117.8 m | 99.5 m | 114.7 m | 98.6 m | 25.4 m | SEC (XBRL)· 18 Nov 2025verified |
| Diluted EPS | 1.24 | 2.13 | 1.85 | 2.21 | 1.97 | 0.53 | SEC (XBRL)· 18 Nov 2025verified |
| Weighted average diluted shares | 54.6 m | 55.2 m | 53.6 m | 51.8 m | 50.1 m | 47.6 m | SEC (XBRL)· 18 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 364.7 m | 479.2 m | 188.7 m | 216.4 m | 209.1 m | 225.7 m | SEC (XBRL)· 18 Nov 2025verified |
| Receivables | 158.8 m | 150.7 m | 136.9 m | 106.2 m | 109.4 m | 137.8 m | SEC (XBRL)· 18 Nov 2025verified |
| Inventories | 314.1 m | 345.7 m | 449.3 m | 492.4 m | 477.3 m | 433.8 m | SEC (XBRL)· 09 Feb 2026verified |
| Current assets | 983.6 m | 1.1 bn | 942.2 m | 962.4 m | 936.0 m | 995.5 m | SEC (XBRL)· 18 Nov 2025verified |
| Property, plant & equipment, net | 370.9 m | 362.6 m | 345.5 m | 337.9 m | 349.1 m | 295.0 m | SEC (XBRL)· 09 Feb 2026verified |
| Goodwill | 1.2 bn | 1.2 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.1 bn | SEC (XBRL)· 09 Feb 2026verified |
| Intangibles (excl. goodwill) | 928.1 m | 906.4 m | 996.6 m | 973.8 m | 948.5 m | 828.2 m | SEC (XBRL)· 09 Feb 2026verified |
| Total assets | 3.5 bn | 3.7 bn | 3.7 bn | 3.7 bn | 3.7 bn | 3.8 bn | SEC (XBRL)· 18 Nov 2025verified |
| Accounts payable | 181.9 m | 209.5 m | 228.8 m | 194.4 m | 219.3 m | 219.7 m | SEC (XBRL)· 18 Nov 2025verified |
| Short-term debt | 0 | 0 | 0 | — | — | — | SEC (XBRL)· 16 Nov 2022verified |
| Long-term debt | 1.2 bn | 1.2 bn | 1.4 bn | 1.4 bn | 1.3 bn | 1.4 bn | SEC (XBRL)· 18 Nov 2025verified |
| Current liabilities | 510.5 m | 536.8 m | 539.5 m | 523.4 m | 563.6 m | 565.5 m | SEC (XBRL)· 18 Nov 2025verified |
| Total liabilities | 2.1 bn | 2.1 bn | 2.2 bn | 2.2 bn | 2.1 bn | 2.2 bn | SEC (XBRL)· 18 Nov 2025verified |
| Equity | 1.4 bn † | 1.6 bn † | 1.5 bn † | 1.5 bn † | 1.6 bn † | 1.6 bn † | SEC (XBRL)· 18 Nov 2025verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 232.6 m | 229.0 m | 102.0 m | -216.1 m | -231.0 m | 118.4 m | SEC (XBRL)· 18 Nov 2025verified |
| Capex | 47.7 m | 56.8 m | 56.4 m | 49.5 m | 56.5 m | 77.0 m | SEC (XBRL)· 18 Nov 2025verified |
| Free cash flow | 184.9 m ≈ | 172.2 m ≈ | 45.6 m ≈ | -265.6 m ≈ | -287.5 m ≈ | 41.4 m ≈ | SEC (XBRL)· 18 Nov 2025derived |
| Investing cash flow | -196.4 m | -48.7 m | -355.4 m | -50.5 m | -62.4 m | -72.9 m | SEC (XBRL)· 18 Nov 2025verified |
| Financing cash flow | -18.7 m | -65.4 m | -17.6 m | -146.5 m | -179.4 m | -30.0 m | SEC (XBRL)· 18 Nov 2025verified |
| Dividends paid | 0 | 25.6 m | 32.6 m | 31.5 m | 30.7 m | 29.3 m | SEC (XBRL)· 18 Nov 2025verified |
| Share repurchases | 0 | 9.2 m | 125.3 m | 75.2 m | 58.5 m | 90.2 m | SEC (XBRL)· 18 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 23 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40 · (margin_of_safety <= -0.25 & agreement in ['high', 'medium'])
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 1.3 bn USD
Key indicators
Coverage and freshness
Score by group
- Returns66
- Growth3
- Balance sheet17
- Valuation22
- Quality23
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 13.44 – 53.11 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)20.03 – 53.11 (Mid 31.34)WACC 7.2% · starting FCFF 110.1 m USD · terminal value share of EV 80%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): -1.6%
- Peers: EV/EBITDA13.44 – 34.96 (Mid 22.75)4 companies used · median multiple 18.9x · quartiles 14.7x – 24.6xCL, COTY, ELF, KVUE
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)19.71 – 26.51 (Mid 22.61)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 23/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 0.6% | 20 (vs peers) | 13% |
| Net margin · Quality | -4.2% | 27 (vs peers) | 8% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 0.8% | 7 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | -34.1% | 0 (on a fixed band) | 10% |
| Net debt / EBITDA · Balance sheet | 8.5x | 0 (vs peers) | 13% |
| Interest coverage · Balance sheet | 0.3x | 0 (on a fixed band) | 8% |
| Current ratio · Balance sheet | 1.8x | 87 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | 21.6x | 0 (on a fixed band) | 13% |
| FCF yield · Valuation | 4.0% | 50 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | 3.4% | 48 (on a fixed band) | 8% |
| Payout ratio (FCF) · Returns | 54.2% | 94 (on a fixed band) | 5% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet17/100 · 3/3 factors with a value
- Growth3/100 · 2/2 factors with a value
- Quality23/100 · 2/3 factors with a value
- Returns66/100 · 2/2 factors with a value
- Valuation22/100 · 2/3 factors with a value
Memo
EDGEWELL PERSONAL CARE COMPANY (EPC). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.2 bn USD in 2025; YoY growth -1.3%; net margin -4.2%; ROE -6.2%; net debt/EBITDA 8.5x.
The estimated value range is 19.71–34.96 USD per share (median of 3 methods, agreement: medium); assumptions are illustrative. Against the central value of 22.75 USD, the price of 28.56 USD leaves a potential of -20.3% (value / price − 1) and a margin of safety of -25.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 23/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 1.8x
- Payout ratio (FCF): 54.2%
What contradicts it
- ROIC: 0.6%
- Net margin: -4.2%
- Revenue CAGR 3Y: 0.8%
- EPS CAGR 3Y: -34.1%
- Net debt / EBITDA: 8.5x
- Interest coverage: 0.3x
- EV/EBITDA: 21.6x
Not assessed (insufficient data or a ratio without meaning): FCF conversion, P/E (TTM).
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +34% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.5 bn | 109.9 | 6.0% | 3.4% | +24.6% | +44% / −7% |
| IPARInterparfums, Inc. | 4.3 bn | 25.5 | 19.5% | 11.3% | +2.5% | +66% / +8% |
| COTYCoty Inc. | 3.4 bn | — | -18.5% | -10.4% | −1.5% | +18% / −66% |
| EPCEdgewell Personal Care Company | 1.3 bn | — | -6.2% | -4.2% | −1.3% | +49% / −21% |
| SLSNSolesence, Inc. | 61.3 m | — | -15.1% | -3.8% | +18.6% | −62% / +16% |
| AXILAxil Brands, Inc. | 35.4 m | 15.5 | 23.3% | 9.3% | +17.5% | +2% / unavailable |
| UGUnited-Guardian, Inc. | 31.2 m | 12.7 | 21.4% | 22.0% | −13.4% | +17% / −16% |
| BNKKBonk, Inc. | 7.8 m | — | -332.4% | -2,330.4% | +201.6% | −84% / −99% |
| CABRCaring Brands, Inc. | 7.8 m | — | -3,889.1% | -183,298.7% | unavailable | −27% / unavailable |
| YCBDcbdMD, Inc. | 4.3 m | — | -40.3% | -13.8% | −1.5% | −37% / −93% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +7% |
| ODDOddity Tech Ltd | — | 11.3 | 32.6% | 13.7% | +25.2% | −53% / −40% |
| ELEstee Lauder Companies Inc | — | 107.3 | 9.3% | 2.4% | +5.0% | +14% / −16% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −70% / −54% |
1- and 3-year price returns: for EPC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Edgewell Personal Care is a global maker and marketer of personal care products spanning wet shaving, sun and skin care. It is refocusing after selling its Feminine Care business, with fiscal 2025 net sales of about 2223.5 million USD, slightly lower year on year, making fiscal 2026 a period of repositioning.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Margin pressurehigh
Rising costs of raw materials, energy and tariffs could reduce margins if they cannot be passed on to customers 13.
- Customer concentrationhigh
A dominant customer could impose tougher trade terms, affecting margins and distribution 1.
- Restructuring executionmedium
Delays in consolidating production could affect product availability and short-term costs 23.
- Regulation and litigationmedium
Growing requirements on ingredients, packaging and environment could generate costs and product liability claims 1.
- Seasonality and weatherlow
Sun care sales depend on season and weather, making quarterly results volatile 1.
Investment thesis
What would need to be true (bull case)
What to watch
- Fourth-quarter results and delivery against the adjusted EPS and adjusted EBITDA outlookQ4 2026
- Organic sales trend in North America and wet shave market share2027
- Completion of Wet Shave manufacturing consolidation and remaining restructuring costsnext 10-K
- Adjusted net debt leverage and use of Feminine Care sale proceedsQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Edgewell Personal Care Company, incorporated in Missouri in 1999 and listed on the NYSE as EPC, runs three segments: Wet Shave, Sun and Skin Care and Feminine Care, with operations in about 20 countries and products sold in more than 50 countries 1. It grew through acquisitions of brands such as Schick, Banana Boat, Hawaiian Tropic, Playtex, Bulldog, Jack Black, Cremo and Billie 1. In November 2025 the board approved selling the Feminine Care segment for 340.0 million USD 1, and the deal closed in February 2026 and is presented as discontinued operations 2. Current results therefore cover continuing operations only 23.
The company sells mainly through a direct sales force supplemented by distributors, and runs its own e-commerce sites including DTC sites for Bulldog, Jack Black and Billie 1. Walmart accounted for about 17.4% of net sales in fiscal 2025, showing a high customer concentration 1.
In the third quarter of fiscal 2026 organic net sales returned to growth, up 1.1% 3, and adjusted EPS was 0.72 USD 3. The fiscal 2026 outlook was narrowed, with adjusted EPS now expected between 1.80 and 2.00 USD 3.
Segments
Wet Shave
The segment includes the Schick, Wilkinson Sword, Edge, Skintimate and Billie brands, and the company considers itself the number two global player in wet shaving 1. In the third quarter of fiscal 2026 organic sales fell slightly on temporary supply constraints in private label, and segment profit declined sharply 3.
Market context
Personal care categories are mature and highly competitive, with large manufacturers competing for consumer acceptance and limited retail shelf space 1. Sun care sales are highly seasonal, peaking from late winter to mid-summer in the US 1. The company expects the global men's grooming market to keep growing 1.
Retailer power and private label brands, usually sold at lower prices, shape pricing and shelf access 1. Cost pressures including tariffs weigh on margins, and the company reported core inflation and net tariffs as headwinds in the third quarter of fiscal 2026 3.
Trends
- Refocusing after the Feminine Care salemixed
Selling the Feminine Care segment could turn the company into a more focused personal care brand owner, and the proceeds reduced borrowings under the revolving credit facility 23.
- Return to growth in North Americatailwind
Organic sales in North America grew in the third quarter of fiscal 2026, supported by volumes in sun care, skin care and grooming 3. If this continues it could support results in the second half of the year 3.
- Cost and tariff pressureheadwind
Raw material inflation, tariffs and trade policy changes reduced adjusted gross margin in recent quarters 13. If these pressures persist they could limit the company's ability to offset cost increases through pricing 1.
- Operational restructuringmixed
Consolidating Mexico operations and Wet Shave manufacturing generated significant restructuring costs 13. If the promised efficiencies materialise they could support margins over the medium term, though short-term costs remain high 3.
Competitive position
In wet shaving the main global rival is The Procter & Gamble Company through its Gillette brand, with The Bic Group and direct-to-consumer newcomers also competing 1. In sun and skin care competition comes from large companies such as Kenvue, Bayer, L'Oréal, The Estee Lauder Companies and Unilever 1.
The company says it keeps its position through recognised brands, formulation and manufacturing efficiency, but it risks losing share to larger rivals with more resources and to private label 1. Bigger competitors can offer aggressive discounts and preferred in-store placement 1.
- The Procter & Gamble CompanyPG
Global leader in wet shaving through the Gillette brand and also a rival in feminine care 1.
- KenvueKVUE
Rival in sun care, skin care and men's grooming 1.
- The Bic Group
Rival in shaving that is expanding beyond its disposable strength 1.
- UnileverUL
Rival in skin care and men's grooming with considerable resources 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Edgewell’s (EPC) Margins Slip Even As North America ReboundsYahoo Finance — News · 15 Sept 2026 · EN
- Schick Razor Maker Edgewell’s Shares Leap on Rejected OfferBloomberg Markets · 23 Jun 2026 · EN
The latest news item in our archive is from 15 Sept 2026; the newest SEC filing is from 23 Sept 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report23 Sept 2026Departure or appointment of officers · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report26 May 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 May 2026
- Current report06 May 2026Results of operations · Financial statements and exhibits
- Quarterly report09 Feb 2026
- Current report09 Feb 2026Results of operations · Departure or appointment of officers · Shareholder vote · Regulation FD disclosure · Financial statements and exhibits
- Current report06 Feb 2026Acquisition or disposition of assets · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement22 Dec 2025
Sources
- [1] Form 10-K, fiscal year ended 2025-09-30 · SEC / Edgewell Personal Care Company · 18 Nov 2025
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Edgewell Personal Care Company · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Edgewell Personal Care Company · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.